Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients

Virological Response ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 3 ◽

Virus Genotype ◽

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2013.05.012 ◽

2013 ◽

Vol 17 (11) ◽

pp. e1017-e1021 ◽

Cited By ~ 5

Author(s):

Uzma Gill ◽

Hafsa Aziz ◽

Muzaffar Lateef Gill

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virological Response ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Rapid Virological Response ◽

Genotype 3 ◽

Duration Of Treatment ◽

Virus Genotype ◽

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4

Annals of Saudi Medicine ◽

10.4103/0256-4947.51816 ◽

2009 ◽

Vol 29 (1) ◽

pp. 4-14 ◽

Cited By ~ 25

Author(s):

Hamad Al Ashgar ◽

Ahmed Helmy ◽

Mohamed Q. Khan ◽

Khalid Al Kahtani ◽

Mohammed Al Quaiz ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virological Response ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Virus Genotype ◽

Genotype 4 ◽

Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C

Digestive Diseases and Sciences ◽

10.1007/s10620-011-1770-3 ◽

2011 ◽

Vol 56 (8) ◽

pp. 2449-2455 ◽

Cited By ~ 25

Author(s):

S. K. Tohra ◽

S. Taneja ◽

S. Ghosh ◽

B. K. Sharma ◽

A. Duseja ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Combination Therapy ◽

Chronic Hepatitis C ◽

Virological Response ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 3 ◽

W1015 Analysis of Sustained Virological Response to Pegylated Interferon & Ribavirin Treatment in Compensated Cirrhosis Due to Hepatitis C Virus, Genotype 3 Infection

Gastroenterology ◽

10.1016/s0016-5085(08)63891-3 ◽

2008 ◽

Vol 134 (4) ◽

pp. A-832

Author(s):

Amna Subhan ◽

Wasim Jafri ◽

Khalid Mumtaz ◽

Saeed S. Hamid ◽

Shahab Abid ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virological Response ◽

Pegylated Interferon ◽

Genotype 3 ◽

Virus Genotype ◽

Compensated Cirrhosis

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

Hepatology ◽

10.1002/hep.21975 ◽

2007 ◽

Vol 47 (1) ◽

pp. 35-42 ◽

Cited By ~ 155

Author(s):

Olav Dalgard ◽

Kristian Bjøro ◽

Helmer Ring-Larsen ◽

Einar Bjornsson ◽

Mona Holberg-Petersen ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virological Response ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Rapid Virological Response ◽

Virus Genotype ◽

Genotype 2 ◽

Faculty of 1000 evaluation for Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718020710.793480337 ◽

2013 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Genotype 1 ◽

Virus Genotype ◽

Double Blind ◽

Phase 2 Trial ◽

Short versus standard treatment with pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial

http://isrctn.org/> ◽

10.1186/isrctn29259563 ◽

2013 ◽

Author(s):

Adriano M Pellicelli

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Standard Treatment ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Virus Genotype ◽

Genotype 2 ◽

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(13)70149-x ◽

2013 ◽

Vol 13 (7) ◽

pp. 597-605 ◽

Cited By ~ 147

Author(s):

Mark Sulkowski ◽

Stanislas Pol ◽

Josep Mallolas ◽

Hugo Fainboim ◽

Curtis Cooper ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Genotype 1 ◽

Virus Genotype ◽

Double Blind ◽

Phase 2 Trial ◽

PG18 A COST-EFFECTIVENESS EVALUATION—RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTSWHO HAVE PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE

Value in Health ◽

10.1016/s1098-3015(10)66722-8 ◽

2008 ◽

Vol 11 (6) ◽

pp. A520

Author(s):

CJ Gibbons ◽

J Morris ◽

AK O'Sullivan

Keyword(s):

Cost Effectiveness ◽

Hepatitis C ◽

Virological Response ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Effectiveness Evaluation ◽

Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3

Gut ◽

10.1136/gut.2010.217323 ◽

2010 ◽

Vol 60 (6) ◽

pp. 879-879 ◽

Cited By ~ 17

Author(s):

H. Patel ◽

E. J. Heathcote

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virological Response ◽

Genotype 3 ◽

Virus Genotype